Share This Page

Support & Insight for the Autumn of Life

THURSDAY: New Alzheimer’s Blood Test – Free Webinar



WEBINAR:

You are cordially invited to a conversation with Dr. David Holtzman about his PrecivityAD groundbreaking new blood test to aid in the diagnosis of Alzheimer’s disease. The blood test is for individuals who are experiencing cognitive impairment. We hope you will join us to learn about this important advancement.


WELLESLEY HILLS, Mass. /PRNewswire/ — Cure Alzheimer’s Fund will host Dr. David Holtzman for a live webinar on Thursday, May 27 at 5:30 PM. Diagnosing Alzheimer’s Disease: A Groundbreaking New Blood Test is free and open to the public. Registration is required.

Dr. Holtzman is a co-inventor of a new blood test, PrecivityAD, designed to assist physicians with diagnosing Alzheimer’s disease. The blood test is the first of its kind to measure beta-amyloid protein, the hallmark of Alzheimer’s disease, to accurately indicate whether someone 60 years of age or older who has memory concerns has the classic pathology of Alzheimer’s in their brain. Since a specific Alzheimer’s diagnosis has previously required expensive and often inaccessible PET imaging scans, his discovery has significant implications for use in clinical practice and treatment trials.

“Cure Alzheimer’s Fund is truly privileged to participate in this webinar with Dr. Holtzman. He is recognized as a giant in Alzheimer’s research and as a caring clinician for the patients he sees,” said Meg Smith, Executive Vice President of Research Management for Cure Alzheimer’s Fund. “As such, he can provide a broad perspective on why this blood test has been so urgently needed and how it will change the patient experience and advance efforts to bring effective treatments to them.” Ms. Smith will moderate the conversation with Dr. Holtzman during the webinar.

Dr. Holtzman, M.D., is the Chair of the Department of Neurology at Washington University School of Medicine in St. Louis and a founding member of the Cure Alzheimer’s Fund Research Leadership Group. His lab has published extensively on the neurobiology of APOE, neuronal activity, glucose, insulin, and the impact of sleep within Alzheimer’s disease.

  • Date: Thursday, May 27th, 2021
  • Time: 5:30 PM Eastern Time
  • Location: Online via ZOOM!
  • Please register for this event using the red bar below.

       REGISTER   

For more information and to register for the May 27th webinar, please visit Cure Alzheimer’s Fund at CureAlz.org.

MORE INFORMATION:

  • Cure Alzheimer’s Fund is a non-profit organization that provides grants to the most promising research to prevent, slow or reverse Alzheimer’s disease. Since its founding in 2004, Cure Alzheimer’s Fund has contributed $125 million to research. Its funded initiatives have been responsible for several key breakthroughs – including the groundbreaking “Alzheimer’s in a Dish” study. With 100 percent of donations going directly to research, Cure Alzheimer’s has been able to support some of the best scientific minds in the field of Alzheimer’s research.

SOURCE:

Email me when people comment
Notify of
guest

This site uses Akismet to reduce spam. Learn how your comment data is processed.

0 Comments
Inline Feedbacks
View all comments
Edited by:
Picture of P. Berger

P. Berger

This site was inspired by my Mom’s autoimmune dementia.

It is a place where we separate out the wheat from the chafe, the important articles & videos from each week’s river of news. Google gets a new post on Alzheimer’s or dementia every 7 minutes. That can overwhelm anyone looking for help. This site filters out, focuses on and offers only the best information. it has helped hundreds of thousands of people since it debuted in 2007. Thanks to our many subscribers for your supportive feedback.

The site is dedicated to all those preserving the dignity of the community of people living with dementia.

Peter Berger, Editor

Share this page To

Related:

Leqembi
Drugs

Leqembi: An Alzheimer’s Drug Worth Rooting For?

At long last, we finally have a disease-modifying drug for Alzheimer’s. The FDA recently approved a new drug that promises to slow the progression of the disease. Only five Alzheimer’s treatments have been approved by the FDA up until a decade ago, and this is only the second to address the progression of the disease.

Read More »
Share to Facebook
Twitter
LinkedIn

This site was inspired by my Mom’s autoimmune dementia.

It is a place where we separate out the wheat from the chafe, the important articles & videos from each week’s river of news. Google gets a new post on Alzheimer’s or dementia every 7 minutes. That can overwhelm anyone looking for help. This site filters out, focuses on and offers only the best information. it has helped hundreds of thousands of people since it debuted in 2007. Thanks to our many subscribers for your supportive feedback.

The site is dedicated to all those preserving the dignity of the community of people living with dementia.

Peter Berger, Editor

Visit Alzheimer's Weekly On

0
Would love your thoughts, please comment.x
()
x
News, Treatments, Care Tips, Diet

Alzheimer's & Dementia Weekly Newsletter: Free

Free. Care & Treatment. Research & Prevention

This site was inspired by my Mom’s autoimmune dementia.

It is a place where we separate out the wheat from the chafe, the important articles & videos from each week’s river of news. Google gets a new post on Alzheimer’s or dementia every 7 minutes. That can overwhelm anyone looking for help. This site filters out, focuses on and offers only the best information. It has helped hundreds of thousands of people since it debuted in 2007. Thanks to our many subscribers for your supportive feedback.

The site is dedicated to all those preserving the dignity of the community of people living with dementia.

Peter Berger, Editor

News to Get at the Truth

Subscribe To Our Weekly Newsletter